|1.||Seidah, Nabil G: 11 articles (12/2013 - 04/2005)|
|2.||Varret, Mathilde: 8 articles (09/2014 - 08/2004)|
|3.||Boileau, Catherine: 7 articles (09/2014 - 08/2004)|
|4.||Abifadel, Marianne: 7 articles (09/2014 - 08/2004)|
|5.||Krempf, Michel: 7 articles (06/2014 - 08/2004)|
|6.||Stein, Evan A: 6 articles (12/2015 - 06/2012)|
|7.||Li, Jian-Jun: 6 articles (04/2015 - 12/2013)|
|8.||Xu, Rui-Xia: 6 articles (04/2015 - 12/2013)|
|9.||Costet, Philippe: 6 articles (01/2013 - 08/2004)|
|10.||Kastelein, John J P: 5 articles (06/2015 - 06/2014)|
01/01/2015 - "Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have emerged as a novel treatment option in patients with hypercholesterolemia. "
06/01/2015 - "Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials."
05/01/2015 - "Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia."
09/01/2014 - "This analysis evaluated the effect of a monoclonal antibody to proprotein convertase subtilisin/kexin 9, alirocumab 150 mg every 2 weeks (Q2W), on Lp(a) levels in pooled data from 3 double-blind, randomized, placebo-controlled, phase 2 studies of 8 or 12 weeks' duration conducted in patients with hypercholesterolemia on background lipid-lowering therapy (NCT01266876, NCT01288469, and NCT01288443). "
03/01/2015 - "Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is in Phase III development for the treatment of hypercholesterolemia. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
10/27/2015 - "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk."
09/15/2015 - "Over the last decade, inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. "
04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive therapeutic target for cardiovascular disease. "
01/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel biomarker of LDL clearance and a therapeutic target of cardiovascular disease. "
06/01/2012 - "Here we tested the hypothesis that ENaC is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), a protease that modulates the risk of cardiovascular disease. "
11/01/2015 - "Bococizumab is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hyperlipidemia. "
06/01/2011 - "The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications."
01/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (encoded by PCSK9) plays a well-known role in the regulation of low-density lipoprotein (LDL) receptors, and an inhibitor of this enzyme is a promising new therapeutic for hyperlipidemia. "
04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-identified member that plays an essential role in cholesterol homeostasis and holds decent promise for hyperlipidemia and coronary artery disease (CAD) treatment. "
02/01/2015 - "Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia."
|4.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
05/01/2015 - "In this article, we will briefly review familial hypercholesterolemia and the role of proprotein convertase subtilisin/kexin 9 inhibitors in this condition. "
05/01/2015 - "The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia."
11/01/2014 - "Identification of the proprotein convertase subtilisin/kexin type 9 (PCSK9) as the third gene causing familial hypercholesterolemia (FH) and understanding its complex biology has led to the discovery of a novel class of therapeutic agents. "
09/01/2014 - "Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation."
11/05/2013 - "Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia."
06/01/2015 - "Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales. "
12/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia."
11/01/2013 - "Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia."
03/01/2015 - "Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. "
10/15/2013 - "Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis."
|1.||Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)
|2.||LDL Receptors (LDL Receptor)
|5.||Serine Proteases (Serine Protease)
|9.||Fibrinogen (Factor I)
|1.||Cardiac Resynchronization Therapy
|4.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)